Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Erlotinib in Advanced HCC
NCT00365391Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Aug 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00365391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365391.